The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies

Abstract excerpt

// Fusheng Zhou 1 , Lili Tang 1 , Siyuan Le 1 , Mei Ge 1 , Dragan Cicic 2 , Fubo Xie 1 , Jinmin Ren 1 , Jiong Lan 1 and Qiang Lu 1 1 GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China 2 Sellas Life Sciences Group, New York, NY 10036, USA Correspondence to: Jiong Lan, email: jlan@genfleet.com Keywords: GFH009; CDK9; cancer; leukemia; cell cycle Received: October 03, 2023 Accepted: November 16, 2023...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Cancer-related Molecular Pathways
• Share to Protein Degradation and Inhibitors